GSK Agrees to Settle Flonase Antitrust Actions for $195 Mil.
Drugmaker GlaxoSmithKline has agreed to settle with plaintiffs for a total of $195 million over allegations that it monopolized the market for its nasal spray Flonase.
This premium content is reserved for The Legal Intelligencer subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now